loader
Please Wait
Applying Filters...

Technical details about BMS-986115, learn more about the structure, uses, toxicity, action, side effects and more

Menu
Xls
2D Structure
Also known as: Bms-986115, 1584647-27-7, Notch inhibitor 1, Bms 986115, Lsk1l593uu, (2s,3r)-n'-[(3s)-5-(3-fluorophenyl)-9-methyl-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide
Molecular Formula
C26H25F7N4O3
Molecular Weight
574.5  g/mol
InChI Key
SRJNRAQUSAVENA-GSHUGGBRSA-N
FDA UNII
LSK1L593UU

GS/pan-Notch Inhibitor AL102 is an orally bioavailable, gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon administration, GS/pan-Notch inhibitor AL102 binds to GS and blocks the proteolytic cleavage and release of the Notch intracellular domain (NICD), which would normally follow ligand binding to the extracellular domain of the Notch receptor. This prevents both the subsequent translocation of NICD to the nucleus to form a transcription factor complex and the expression of Notch-regulated genes. This results in the induction of apoptosis and the inhibition of growth of tumor cells that overexpress Notch. Overexpression of the Notch signaling pathway plays an important role in tumor cell proliferation and survival. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains and leads to their activation.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S,3R)-N'-[(3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide
2.1.2 InChI
InChI=1S/C26H25F7N4O3/c1-13-4-2-7-18-19(13)36-24(40)22(35-20(18)14-5-3-6-15(27)12-14)37-23(39)17(9-11-26(31,32)33)16(21(34)38)8-10-25(28,29)30/h2-7,12,16-17,22H,8-11H2,1H3,(H2,34,38)(H,36,40)(H,37,39)/t16-,17+,22+/m0/s1
2.1.3 InChI Key
SRJNRAQUSAVENA-GSHUGGBRSA-N
2.1.4 Canonical SMILES
CC1=C2C(=CC=C1)C(=NC(C(=O)N2)NC(=O)C(CCC(F)(F)F)C(CCC(F)(F)F)C(=O)N)C3=CC(=CC=C3)F
2.1.5 Isomeric SMILES
CC1=C2C(=CC=C1)C(=N[C@@H](C(=O)N2)NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(=O)N)C3=CC(=CC=C3)F
2.2 Other Identifiers
2.2.1 UNII
LSK1L593UU
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (2r,3s)-n-((3s)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1h-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide

2. Bms-986115

3. Butanediamide, N1-((3s)-5-(3-fluorophenyl)-2,3-dihydro-9-methyl-2-oxo-1h-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)-, (2r,3s)-

2.3.2 Depositor-Supplied Synonyms

1. Bms-986115

2. 1584647-27-7

3. Notch Inhibitor 1

4. Bms 986115

5. Lsk1l593uu

6. (2s,3r)-n'-[(3s)-5-(3-fluorophenyl)-9-methyl-2-oxo-1,3-dihydro-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide

7. Chembl3911164

8. Schembl15608290

9. Bms986115

10. Nsc836050

11. Bms 986115 [who-dd]

12. Db13126

13. Nsc-836050

14. (2r,3s)-n-((3s)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1h-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide

15. Hy-12860

16. Cs-0012731

17. P14960

18. Us9273014, 1

19. Q27283163

20. (2r,3s)-n1-((s)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide

21. Butanediamide, N1-((3s)-5-(3-fluorophenyl)-2,3-dihydro-9-methyl-2-oxo-1h-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)-, (2r,3s)-

2.4 Create Date
2014-04-07
3 Chemical and Physical Properties
Molecular Weight 574.5 g/mol
Molecular Formula C26H25F7N4O3
XLogP34.8
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count11
Rotatable Bond Count9
Exact Mass574.18148781 g/mol
Monoisotopic Mass574.18148781 g/mol
Topological Polar Surface Area114 Ų
Heavy Atom Count40
Formal Charge0
Complexity956
Isotope Atom Count0
Defined Atom Stereocenter Count3
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Gamma Secretase Inhibitors and Modulators

Agents that suppress GAMMA-SECRETASE by inhibiting or modulating its activities. Targeted enzymatic activities include its involvement in accumulation of toxic AMYLOID BETA-PEPTIDES (e.g., Aβ42) in ALZHEIMER DISEASE and activation of NOTCH RECEPTOR mediated SIGNAL PATHWAYS in certain cancer types. (See all compounds classified as Gamma Secretase Inhibitors and Modulators.)